TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07146386: A Randomized, Double-blind, Controlled, Non-inferiority Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of H077 Sustained-release Tablets Versus Silodosin Capsules in the Treatment of Benign Prost

Sponsor: Shanghai Huilun Pharmaceutical Co., Ltd. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 728 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,031,696

Rescue Site Savings

+$7,260,176

Unlock Full NCT07146386 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07146386 Rescue Dossier →